Medicare Part B and Part D drug eligibility for center for Medicare and Medicaid Services price negotiation under the Inflation Reduction Act: estimates using 2016-2019 data

• Päätekijät: Omar Qureshi (Tekijä), Reshma Ramachandran (Tekijä), Joseph S. Ross (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

ABSTRACTBackground To reduce Medicare prescription drug expenditures, the 2022 Inflation Reduction Act (IRA) allows the Centers for Medicare & Medicaid Services (CMS) to directly negotiate with drug manufacturers on Medicare prices of high-expenditure drugs (≥$200m annual spending) which meet ce...